CompletedNot Applicable

Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients

Italy125 participantsStarted 2023-09-29

Plain-language summary

The goal of this retrospective observational study is to investigate any possible association among tacrolimus (TAC) blood concentrations, clinical efficacy and tolerability. Therefore, the main questions it aims to answer are: 1. to clarify which variables, how and to what extent influence daily TAC blood concentrations in pediatric allo-hematopoietic stem cell transplantation (HSCT) recipients; 2. to investigate the incidence of graft-versus-host disease (GVHD) and graft failure according to TAC exposure. Pediatric patients administered TAC to prevent GVHD after an allogeneic bone marrow transplantation.

Who can participate

Age range1 Month – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age of the patients between 0 and 18 years (pediatric) * Patients undergoing allogeneic bone marrow transplantation * Patients' GVHD prophylaxis with tacrolimus * Signed informed consent Exclusion Criteria: * Patients undergoing autologous bone marrow transplantation * Patients not undergoing GVHD prophylaxis * Patients undergoing cyclosporin prophylaxis * Incomplete pharmacokinetic/pharmacodynamic data * Lack of any informed consent

What they're measuring

TAC pharmacokinetics

Timeframe: 0-30 days

Trial details

NCT IDNCT06080490

SponsorUniversity of Pisa

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09-29

View on ClinicalTrials.gov More Graft Vs Host Disease trials